RhumbLine Advisers
SLN icon

RhumbLine Advisers’s Silence Therapeutics SLN Stock Holding History

RhumbLine Advisers’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$132K Sell
12,088
-1,727
-13% -$21K ﹤0.01% 3431
2026
Q2 		$152K Sell
13,815
-120
-0.9% -$844 ﹤0.01% 3391
2026
Q1 		$73.4K Buy
13,935
+936
+7% +$5.15K ﹤0.01% 3513
2025
Q4 		$79K Buy
12,999
+7,134
+122% +$45.7K ﹤0.01% 3545
2025
Q3 		$30.4K Sell
5,865
-331
-5% -$1.84K ﹤0.01% 3728
2025
Q2 		$35.9K Buy
6,196
+4,321
+230% +$18.5K ﹤0.01% 3723
2025
Q1 		$5.28K Buy
1,875
+1,034
+123% +$5.05K ﹤0.01% 3897
2024
Q4 		$5.78K Buy
841
+87
+12% +$1.12K ﹤0.01% 3935
2024
Q3 		$13.7K Buy
754
+285
+61% +$5.3K ﹤0.01% 3853
2024
Q2 		$8.91K Buy
469
+454
+3,027% +$9.7K ﹤0.01% 3998
2024
Q1 		$324 Buy
15
+10
+200% +$217 ﹤0.01% 4200
2023
Q4 		$86 Hold
5
– – ﹤0.01% 4251
2023
Q3 		$49 Buy
+5
New +$37 ﹤0.01% 4290

Other funds holding SLN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $313B AUM 26.62% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return

RhumbLine Advisers's SLN Position: Q3 2026 in Review

RhumbLine Advisers reduced its Silence Therapeutics (SLN) stake by 13% in Q3 2026, selling an estimated $21K and leaving 12,088 shares worth $132K. The position accounts for ﹤0.01% of the portfolio, ranked #3431.

RhumbLine Advisers first reported a position in SLN in Q3 2023 and has held it in 13 quarters since. The position peaked at $152K in Q2 2026. 24 funds tracked by Wall St. Rank hold SLN as of Q3 2026.

  • RhumbLine Advisers held 12,088 shares of Silence Therapeutics worth $132K as of Q3 2026.
  • RhumbLine Advisers sold 1,727 Silence Therapeutics shares in Q3 2026, an estimated $21K.
  • Silence Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #3431 holding.
  • RhumbLine Advisers first reported a position in Silence Therapeutics in Q3 2023 and has held it in 13 quarters since.
  • RhumbLine Advisers's Silence Therapeutics position peaked at $152K in Q2 2026.
  • 24 funds tracked by Wall St. Rank held Silence Therapeutics as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.